347 related articles for article (PubMed ID: 32504051)
1. Pre-clinical modeling of cutaneous melanoma.
Rebecca VW; Somasundaram R; Herlyn M
Nat Commun; 2020 Jun; 11(1):2858. PubMed ID: 32504051
[TBL] [Abstract][Full Text] [Related]
2. Individualized strategies to target specific mechanisms of disease in malignant melanoma patients displaying unique mutational signatures.
Curiel-Olmo S; García-Castaño A; Vidal R; Pisonero H; Varela I; León-Castillo A; Trillo E; González-Vela C; García-Diaz N; Almaraz C; Moreno T; Cereceda L; Madureira R; Martinez N; Ortiz-Romero P; Valdizán E; Piris MA; Vaqué JP
Oncotarget; 2015 Sep; 6(28):25452-65. PubMed ID: 26327537
[TBL] [Abstract][Full Text] [Related]
3. Model Systems for the Study of Malignant Melanoma.
Gregg RK
Methods Mol Biol; 2021; 2265():1-21. PubMed ID: 33704702
[TBL] [Abstract][Full Text] [Related]
4. The Dietary Supplement Chondroitin-4-Sulfate Exhibits Oncogene-Specific Pro-tumor Effects on BRAF V600E Melanoma Cells.
Lin R; Xia S; Shan C; Chen D; Liu Y; Gao X; Wang M; Kang HB; Pan Y; Liu S; Chung YR; Abdel-Wahab O; Merghoub T; Rossi M; Kudchadkar RR; Lawson DH; Khuri FR; Lonial S; Chen J
Mol Cell; 2018 Mar; 69(6):923-937.e8. PubMed ID: 29547721
[TBL] [Abstract][Full Text] [Related]
5. Patient-derived tumor xenograft models for melanoma drug discovery.
Harris AL; Joseph RW; Copland JA
Expert Opin Drug Discov; 2016 Sep; 11(9):895-906. PubMed ID: 27454070
[TBL] [Abstract][Full Text] [Related]
6. Wild-type KRAS is a novel therapeutic target for melanoma contributing to primary and acquired resistance to BRAF inhibition.
Dietrich P; Kuphal S; Spruss T; Hellerbrand C; Bosserhoff AK
Oncogene; 2018 Feb; 37(7):897-911. PubMed ID: 29059159
[TBL] [Abstract][Full Text] [Related]
7. BET inhibitor suppresses melanoma progression
Deng G; Zeng F; Su J; Zhao S; Hu R; Zhu W; Hu S; Chen X; Yin M
Theranostics; 2020; 10(25):11428-11443. PubMed ID: 33052224
[No Abstract] [Full Text] [Related]
8. Melanoma patient-derived xenografts accurately model the disease and develop fast enough to guide treatment decisions.
Einarsdottir BO; Bagge RO; Bhadury J; Jespersen H; Mattsson J; Nilsson LM; Truvé K; López MD; Naredi P; Nilsson O; Stierner U; Ny L; Nilsson JA
Oncotarget; 2014 Oct; 5(20):9609-18. PubMed ID: 25228592
[TBL] [Abstract][Full Text] [Related]
9. Isolation and characterization of two canine melanoma cell lines: new models for comparative oncology.
Segaoula Z; Primot A; Lepretre F; Hedan B; Bouchaert E; Minier K; Marescaux L; Serres F; Galiègue-Zouitina S; André C; Quesnel B; Thuru X; Tierny D
BMC Cancer; 2018 Dec; 18(1):1219. PubMed ID: 30514258
[TBL] [Abstract][Full Text] [Related]
10. COX-2 as a potential biomarker and therapeutic target in melanoma.
Tudor DV; Bâldea I; Lupu M; Kacso T; Kutasi E; Hopârtean A; Stretea R; Gabriela Filip A
Cancer Biol Med; 2020 Feb; 17(1):20-31. PubMed ID: 32296574
[TBL] [Abstract][Full Text] [Related]
11. Genetically engineered cancer models, but not xenografts, faithfully predict anticancer drug exposure in melanoma tumors.
Combest AJ; Roberts PJ; Dillon PM; Sandison K; Hanna SK; Ross C; Habibi S; Zamboni B; Müller M; Brunner M; Sharpless NE; Zamboni WC
Oncologist; 2012; 17(10):1303-16. PubMed ID: 22993143
[TBL] [Abstract][Full Text] [Related]
12. Gene expression analyses of primary melanomas reveal CTHRC1 as an important player in melanoma progression.
Eriksson J; Le Joncour V; Nummela P; Jahkola T; Virolainen S; Laakkonen P; Saksela O; Hölttä E
Oncotarget; 2016 Mar; 7(12):15065-92. PubMed ID: 26918341
[TBL] [Abstract][Full Text] [Related]
13. Efficient Suppression of NRAS-Driven Melanoma by Co-Inhibition of ERK1/2 and ERK5 MAPK Pathways.
Adam C; Fusi L; Weiss N; Goller SG; Meder K; Frings VG; Kneitz H; Goebeler M; Houben R; Schrama D; Schmidt M
J Invest Dermatol; 2020 Dec; 140(12):2455-2465.e10. PubMed ID: 32376279
[TBL] [Abstract][Full Text] [Related]
14. The role of BPTF in melanoma progression and in response to BRAF-targeted therapy.
Dar AA; Nosrati M; Bezrookove V; de Semir D; Majid S; Thummala S; Sun V; Tong S; Leong SP; Minor D; Billings PR; Soroceanu L; Debs R; Miller JR; Sagebiel RW; Kashani-Sabet M
J Natl Cancer Inst; 2015 Feb; 107(5):. PubMed ID: 25713167
[TBL] [Abstract][Full Text] [Related]
15. Ultraviolet light and melanoma.
Craig S; Earnshaw CH; Virós A
J Pathol; 2018 Apr; 244(5):578-585. PubMed ID: 29380860
[TBL] [Abstract][Full Text] [Related]
16. A novel immunogenic mouse model of melanoma for the preclinical assessment of combination targeted and immune-based therapy.
Lelliott EJ; Cullinane C; Martin CA; Walker R; Ramsbottom KM; Souza-Fonseca-Guimaraes F; Abuhammad S; Michie J; Kirby L; Young RJ; Slater A; Lau P; Meeth K; Oliaro J; Haynes N; McArthur GA; Sheppard KE
Sci Rep; 2019 Feb; 9(1):1225. PubMed ID: 30718660
[TBL] [Abstract][Full Text] [Related]
17. MicroRNA-22 targets FMNL2 to inhibit melanoma progression via the regulation of the Wnt/β-catenin signaling pathway and epithelial-mesenchymal transition.
Shi L; Huo JW; Chen SS; Xue JX; Gao WY; Li XY; Song YH; Xu HT; Zhu XW; Chen K
Eur Rev Med Pharmacol Sci; 2019 Jun; 23(12):5332-5342. PubMed ID: 31298385
[TBL] [Abstract][Full Text] [Related]
18. Establishment of Two Dimensional (2D) and Three-Dimensional (3D) Melanoma Primary Cultures as a Tool for In Vitro Drug Resistance Studies.
Cruz Rodríguez N; Lineros J; Rodríguez CS; Martínez LM; Rodríguez JA
Methods Mol Biol; 2019; 1913():119-131. PubMed ID: 30666602
[TBL] [Abstract][Full Text] [Related]
19. EZH2 Cooperates with DNA Methylation to Downregulate Key Tumor Suppressors and IFN Gene Signatures in Melanoma.
Tiffen J; Gallagher SJ; Filipp F; Gunatilake D; Emran AA; Cullinane C; Dutton-Register K; Aoude L; Hayward N; Chatterjee A; Rodger EJ; Eccles MR; Hersey P
J Invest Dermatol; 2020 Dec; 140(12):2442-2454.e5. PubMed ID: 32360600
[TBL] [Abstract][Full Text] [Related]
20. Development of a human three-dimensional organotypic skin-melanoma spheroid model for in vitro drug testing.
Vörsmann H; Groeber F; Walles H; Busch S; Beissert S; Walczak H; Kulms D
Cell Death Dis; 2013 Jul; 4(7):e719. PubMed ID: 23846221
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
